Cargando…

Case Report: Durable Response to the Combination of Brigatinib and Cetuximab Plus Icotinib in a NSCLC Patient Harboring EGFR L858R-T790M-cis-G796S and L718Q Resistance Mutations Following Progression With Osimertinib

The efficacy of osimertinib is severely limited by the emergence of EGFR C797S, which is detected in either the cis or trans position with T790M when osimertinib is used as a second-line treatment, and which is largely identified in combination with an EGFR 19 deletion. The EGFR T790M-cis-G796S muta...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Yubo, Han, Rui, Zhu, Mengxiao, He, Tingting, He, Yong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9071300/
https://www.ncbi.nlm.nih.gov/pubmed/35530305
http://dx.doi.org/10.3389/fonc.2022.875313
_version_ 1784700821398618112
author Wang, Yubo
Han, Rui
Zhu, Mengxiao
He, Tingting
He, Yong
author_facet Wang, Yubo
Han, Rui
Zhu, Mengxiao
He, Tingting
He, Yong
author_sort Wang, Yubo
collection PubMed
description The efficacy of osimertinib is severely limited by the emergence of EGFR C797S, which is detected in either the cis or trans position with T790M when osimertinib is used as a second-line treatment, and which is largely identified in combination with an EGFR 19 deletion. The EGFR T790M-cis-G796S mutation, which also occurs in exon 20 as C797S, participates in osimertinib resistance. To date, limited data for overcoming this resistance mutation have been reported. Here, we report data for an advanced NSCLC patient who developed EGFR L858R-T790M-cis-G796S and EGFR L718Q resistance co-mutations following progression with osimertinib. Such a case has rarely been reported, and under chemotherapy guidelines for this situation, no other effective treatment is recommended. The patient in our case experienced remarkable clinical improvement and good tolerance to the combination target therapy of brigatinib and cetuximab plus icotinib. At the time of our patient’s last follow-up and prior to publication, our patient had reached more than 9 months of progression-free survival (PFS) and felt very well. Our finding provides clinical evidence that the combined target therapy of brigatinib and cetuximab may potentially be an effective treatment strategy for patients with an acquired EGFR T790M-cis-G796S resistance mutation following osimertinib treatment.
format Online
Article
Text
id pubmed-9071300
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-90713002022-05-06 Case Report: Durable Response to the Combination of Brigatinib and Cetuximab Plus Icotinib in a NSCLC Patient Harboring EGFR L858R-T790M-cis-G796S and L718Q Resistance Mutations Following Progression With Osimertinib Wang, Yubo Han, Rui Zhu, Mengxiao He, Tingting He, Yong Front Oncol Oncology The efficacy of osimertinib is severely limited by the emergence of EGFR C797S, which is detected in either the cis or trans position with T790M when osimertinib is used as a second-line treatment, and which is largely identified in combination with an EGFR 19 deletion. The EGFR T790M-cis-G796S mutation, which also occurs in exon 20 as C797S, participates in osimertinib resistance. To date, limited data for overcoming this resistance mutation have been reported. Here, we report data for an advanced NSCLC patient who developed EGFR L858R-T790M-cis-G796S and EGFR L718Q resistance co-mutations following progression with osimertinib. Such a case has rarely been reported, and under chemotherapy guidelines for this situation, no other effective treatment is recommended. The patient in our case experienced remarkable clinical improvement and good tolerance to the combination target therapy of brigatinib and cetuximab plus icotinib. At the time of our patient’s last follow-up and prior to publication, our patient had reached more than 9 months of progression-free survival (PFS) and felt very well. Our finding provides clinical evidence that the combined target therapy of brigatinib and cetuximab may potentially be an effective treatment strategy for patients with an acquired EGFR T790M-cis-G796S resistance mutation following osimertinib treatment. Frontiers Media S.A. 2022-04-21 /pmc/articles/PMC9071300/ /pubmed/35530305 http://dx.doi.org/10.3389/fonc.2022.875313 Text en Copyright © 2022 Wang, Han, Zhu, He and He https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Wang, Yubo
Han, Rui
Zhu, Mengxiao
He, Tingting
He, Yong
Case Report: Durable Response to the Combination of Brigatinib and Cetuximab Plus Icotinib in a NSCLC Patient Harboring EGFR L858R-T790M-cis-G796S and L718Q Resistance Mutations Following Progression With Osimertinib
title Case Report: Durable Response to the Combination of Brigatinib and Cetuximab Plus Icotinib in a NSCLC Patient Harboring EGFR L858R-T790M-cis-G796S and L718Q Resistance Mutations Following Progression With Osimertinib
title_full Case Report: Durable Response to the Combination of Brigatinib and Cetuximab Plus Icotinib in a NSCLC Patient Harboring EGFR L858R-T790M-cis-G796S and L718Q Resistance Mutations Following Progression With Osimertinib
title_fullStr Case Report: Durable Response to the Combination of Brigatinib and Cetuximab Plus Icotinib in a NSCLC Patient Harboring EGFR L858R-T790M-cis-G796S and L718Q Resistance Mutations Following Progression With Osimertinib
title_full_unstemmed Case Report: Durable Response to the Combination of Brigatinib and Cetuximab Plus Icotinib in a NSCLC Patient Harboring EGFR L858R-T790M-cis-G796S and L718Q Resistance Mutations Following Progression With Osimertinib
title_short Case Report: Durable Response to the Combination of Brigatinib and Cetuximab Plus Icotinib in a NSCLC Patient Harboring EGFR L858R-T790M-cis-G796S and L718Q Resistance Mutations Following Progression With Osimertinib
title_sort case report: durable response to the combination of brigatinib and cetuximab plus icotinib in a nsclc patient harboring egfr l858r-t790m-cis-g796s and l718q resistance mutations following progression with osimertinib
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9071300/
https://www.ncbi.nlm.nih.gov/pubmed/35530305
http://dx.doi.org/10.3389/fonc.2022.875313
work_keys_str_mv AT wangyubo casereportdurableresponsetothecombinationofbrigatinibandcetuximabplusicotinibinansclcpatientharboringegfrl858rt790mcisg796sandl718qresistancemutationsfollowingprogressionwithosimertinib
AT hanrui casereportdurableresponsetothecombinationofbrigatinibandcetuximabplusicotinibinansclcpatientharboringegfrl858rt790mcisg796sandl718qresistancemutationsfollowingprogressionwithosimertinib
AT zhumengxiao casereportdurableresponsetothecombinationofbrigatinibandcetuximabplusicotinibinansclcpatientharboringegfrl858rt790mcisg796sandl718qresistancemutationsfollowingprogressionwithosimertinib
AT hetingting casereportdurableresponsetothecombinationofbrigatinibandcetuximabplusicotinibinansclcpatientharboringegfrl858rt790mcisg796sandl718qresistancemutationsfollowingprogressionwithosimertinib
AT heyong casereportdurableresponsetothecombinationofbrigatinibandcetuximabplusicotinibinansclcpatientharboringegfrl858rt790mcisg796sandl718qresistancemutationsfollowingprogressionwithosimertinib